

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of January 2013.

Commission File Number: 000-54771

Acasti Pharma Inc.

(Translation of registrant's name into English)

545 PROMENADE DU CENTROPOLIS, SUITE 100

LAVAL QUEBEC H7T 0A3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [] Form 40-F [x]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

On January 15, 2013 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated January 15, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Acasti Pharma Inc.

(Registrant)

Date: January 15, 2013

/s/ HENRI HARLAND

Henri Harland
CEO

Acasti Pharma Reports Its Third Quarter Results

LAVAL, Quebec, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX.V:APO), a Neptune Technologies & Bioresources Inc. ("Neptune") subsidiary, reports the highlights of its financial results for the third quarter, ended November 30, 2012.

Financial Results Highlights – Third Quarter

- During the three-month period ended November 30, 2012 Acasti generated revenues of \$424,000 from sales of Onemia™, while Acasti did not generate revenues from sales during the corresponding period of 2011.
- Research and development expenses for the three-month period ended November 30, 2012, amounted to \$770,000 compared to \$1,363,000 for the corresponding period of 2011.
- Adjusted EBITDA for the three-month period ended November 30, 2012 was negative \$1,036,000, compared to negative \$1,677,000 obtained during the corresponding period of 2011.
- Net loss amounted to \$1,611,000, or \$0.02 per share for the three-month period ended November 30, 2012 compared to \$2,207,000, or \$0.03 per share, for the corresponding period of 2011.

Financial Results Highlights – Nine-month period

- During the nine-month period ended November 30, 2012 Acasti generated revenues of \$675,000 from sales of Onemia™, while Acasti did not generate revenues from sales during the corresponding period of 2011.
- Research and development expenses for the nine-month period ended November 30, 2012, amounted to \$2,091,000 compared to \$2,719,000 for the corresponding period of 2011.
- Adjusted EBITDA for the nine-month period ended November 30, 2012 was negative \$2,989,000, compared to negative \$3,624,000 obtained during the corresponding period of 2011.
- Net loss amounted to \$4,940,000, or \$0.07 per share for the nine-month period ended November 30, 2012 compared to \$4,954,000, or \$0.08 per share, for the corresponding period of 2011.

"Our continued commercialization efforts have translated into a second consecutive quarter with sales of Onemia™ in the medical food market, providing further endorsement of our corporate development strategy by generating short-term revenues to partially finance our research & development program," stated Xavier Harland, Chief Financial Officer.

"Acasti achieved important milestones over the last few months, including; the prepayment of Neptune's royalties making Acasti royalty free, its first clinical trial insight indicating an approximate 25% reduction in triglycerides at a 2g dose of CaPre® and more recently the listing on NASDAQ. All of these accomplishments are pivotal developments, preceding the expected completion of our open-label clinical trial in the coming months," stated Harlan Waksal, Executive Vice-President.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking

statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:

Xavier Harland
Chief Financial Officer
+1.450.687.2262
x.harland@acastipharma.com
www.acastipharma.com

Howard Group Contact:

Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com